gadolinium dtpa has been researched along with isoxazoles in 1 studies
| Studies (gadolinium dtpa) | Trials (gadolinium dtpa) | Recent Studies (post-2010) (gadolinium dtpa) | Studies (isoxazoles) | Trials (isoxazoles) | Recent Studies (post-2010) (isoxazoles) |
|---|---|---|---|---|---|
| 12,654 | 664 | 4,051 | 8,633 | 900 | 3,337 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Beattie, BJ; Blasberg, RG; Malkin, MG; Thiessen, B; Vlassenko, AG | 1 |
1 other study(ies) available for gadolinium dtpa and isoxazoles
| Article | Year |
|---|---|
Evaluation of early response to SU101 target-based therapy in patients with recurrent supratentorial malignant gliomas using FDG PET and Gd-DTPA MRI.
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Biological Transport, Active; Carmustine; Chemotherapy, Adjuvant; Combined Modality Therapy; Cranial Irradiation; Disease Progression; Disease-Free Survival; Energy Metabolism; Female; Fluorodeoxyglucose F18; Gadolinium DTPA; Glioblastoma; Glucose; Humans; Isoxazoles; Leflunomide; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Recurrence, Local; Platelet-Derived Growth Factor; Prognosis; Signal Transduction; Supratentorial Neoplasms; Tomography, Emission-Computed; Treatment Outcome | 2000 |